Lilly’s oral GLP-1 racks up two more clinical wins in diabetes
Eli Lilly’s GLP-1 pill has succeeded in two more late-stage trials in type 2 diabetes. The company said Wednesday that orforglipron beat AstraZeneca’s Farxiga at lowering patients’ blood sugar levels in …
Lilly, battling skepticism, reinforces GLP-1 pill’s case with new study data
Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where on Wednesday it succeeded in two more late-stage trials.
GLP-1 Receptor Agonists in Patients with Diabetes and Peripheral Artery Disease – In Pursuit of Excellence
Perfection is not attainable, but if we chase perfection, we can catch excellence.”- Vince Lombardi
Muscle Loss on GLP-1s: How Nutrition and Strength Tracking Help
In the early weeks of a GLP-1 journey, the changes can feel exciting. You may be free from nagging cravings and start to see changes on the scale. But without the right habits, GLP-1s can lead to muscle loss, which is not the kind of weight you typically want to lose (1). The good news? […]
Eli Lilly’s orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins
Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek approval in the indication next year.
STAT+: Pharmalittle: We’re reading about an experimental Lilly weight loss pill, a big biotech funding deal, and more
Top of the morning to you. The middle of the week is upon us and, since you made it this far, why not forge ahead? After all, there is always light at the end of the proverbial tunnel. You never know what you may accomplish. So please join us as we celebrate this notion with […]
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
After a muted start to 2025, Big Pharma is back on the M&A trail. In just a month, three major players — Pfizer PFE, Novo Nordisk NVO and Roche RHHBY — announced multi-billion-dollar deals targeting the fast-growing, lucrative metabolic and obesity-related disease space. Pfizer Takes Another Shot at Obesity Last month, this U.S.-based pharma giant […]
Fake GLP-1 Drugs Go Viral: France Launches Crackdown
France’s medicines agency has referred multiple cases to prosecutors and has filed 20 reports against illicit sites through its cybercrime platform, Pharos. Medscape Medical News
Lilly’s weight-loss pill shows better blood sugar control in late-stage trials
Eli Lilly’s experimental oral weight-loss drug, orforglipron, demonstrated superior blood sugar control in diabetic patients across two late-stage trials. The drug, designed to mimic the GLP-1 hormone, showed significant A1C reductions and weight loss, potentially setting a new standard of care for type 2 diabetes.
Consensus: Bisphosphonates for Aromatase Inhibitor Bone Loss
The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture risk linked to aromatase inhibitor use in hormone-sensitive breast cancer. Medscape Medical News